<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742621</url>
  </required_header>
  <id_info>
    <org_study_id>20-04021768</org_study_id>
    <nct_id>NCT04742621</nct_id>
  </id_info>
  <brief_title>Liver Transplantation for Unresectable Liver Limited Colorectal Metastases</brief_title>
  <official_title>Liver Transplantation for Unresectable Liver Limited Colorectal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, single institution pilot registry of liver transplantation in patients&#xD;
      with unresectable colorectal liver-only metastases at Weill Cornell Medical College. Patients&#xD;
      with liver predominant colorectal liver metastases will be screened based on eligibility&#xD;
      criteria in a specified clinical hepatobiliary and colorectal liver metastasis tumor board&#xD;
      consisting of the principal and co-investigators, representing medical oncology, transplant&#xD;
      surgery, radiology, and pathology. The registry aims to track basic demographic data as well&#xD;
      as referral patterns, in addition to specific oncologic data such as tumor burden, extent of&#xD;
      disease, extent of disease on explant, recurrence rates, patterns of recurrence and survival&#xD;
      rates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 27, 2035</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2034</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>To develop a registry of liver transplantation in patients with liver limited metastatic colorectal cancer at Weill Cornell Medical College / New York-Presbyterian Hospital (WCMC / NYPH)</measure>
    <time_frame>25 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine disease-free survival (DFS) in patients that receive a liver transplant for metastatic colorectal cancer at Weill Cornell Medical College / New York-Presbyterian Hospital</measure>
    <time_frame>25 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine overall survival (OS) in patients that receive a liver transplant for metastatic colorectal cancer at Weill Cornell Medical College / New York-Presbyterian Hospital</measure>
    <time_frame>25 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Unresectable Liver-limited Colorectal Metastases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver transplant</intervention_name>
    <description>Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver predominant colorectal liver metastases will be screened based on&#xD;
        eligibility criteria in a specified clinical hepatobiliary and colorectal liver metastasis&#xD;
        tumor board. If deemed acceptable candidates for liver transplantation, they will then&#xD;
        undergo transplant evaluation as per Weill Cornell Medical College Liver Transplant&#xD;
        clinical protocols.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
          2. No evidence of extrahepatic metastases or local recurrence based on PET/CT and&#xD;
             colonoscopy&#xD;
&#xD;
          3. No signs of extrahepatic metastases or local recurrence according to PET/CT 4 weeks&#xD;
             prior to consideration of transplant&#xD;
&#xD;
          4. Age 18-65 years old&#xD;
&#xD;
          5. Good performance status with ECOG 0-1&#xD;
&#xD;
          6. Stability or regression of liver metastasis for at least 6 months&#xD;
&#xD;
          7. Minimum of 1 year between diagnosis of colon cancer and liver transplant and 6 months&#xD;
             from primary tumor resection and liver transplant&#xD;
&#xD;
          8. Minimum of 6 months chemotherapy&#xD;
&#xD;
          9. CEA &lt; 200 ug/L 3 months prior to transplant&#xD;
&#xD;
         10. Adequate organ and marrow function with Hb &gt; 10 g/dL, ANC &gt; 1000/uL, platelets &gt;&#xD;
             100,000/uL, bilirubin &lt; 2x ULN, AST/ALT &lt; 5x ULN, Creatinine &lt; 1.25 x ULN, Albumin&#xD;
             above LLN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of extrahepatic disease or local recurrence&#xD;
&#xD;
          2. Previous resection of lung metastases&#xD;
&#xD;
          3. MSI-H/dMMR or BRAF mutation&#xD;
&#xD;
          4. Any other medical or co-morbid condition that would preclude liver transplantation, as&#xD;
             determined by the transplant team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Halazun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Halazun, MD</last_name>
    <phone>212-746-2127</phone>
    <email>kah7007@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Halazun, MD</last_name>
      <phone>212-746-2127</phone>
      <email>kah7007@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Halazun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gagandeep Brar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

